A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bourgas, Bulgaria, 8000
-
Haskovo, Bulgaria, 6300
-
Pleven, Bulgaria, 5800
-
Plovdiv, Bulgaria, 4004
-
Sofia, Bulgaria, 1757
-
Sofia, Bulgaria, 1784
-
Varna, Bulgaria, 9002
-
Varna, Bulgaria, 9010
-
Vratza, Bulgaria, 3000
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults at least 18 years of age
- Malignant bone disease due to multiple myeloma or cancer of the lung, prostate, gastrointestinal (GI) tract, ovary, or bladder
- Bone pain defined as a Brief Pain Inventory (BPI) most acute pain score greater than or equal to 4
- Radiologically confirmed bone disease disease
Exclusion Criteria:
- Previous treatment with ibandronate (Bondronat) within previous 2 months
- Severely impaired renal function
- Known brain metastases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ibandronate IV Infusion
Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
|
Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Other Names:
|
|
Experimental: Ibandronate PO Tablet
Participants will receive ibandronate, 50 mg PO daily, for 4 months.
|
Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Response rate according to reduction in BPI most acute pain score from Baseline
Time Frame: Month 4
|
Month 4
|
|
Change in KPI
Time Frame: Baseline to Month 4
|
Baseline to Month 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to onset of decrease in most acute pain score
Time Frame: Up to 4 months
|
Up to 4 months
|
|
Analgesic consumption according to participant diary
Time Frame: Up to 5 months
|
Up to 5 months
|
|
Incidence of adverse events
Time Frame: Up to 5 months
|
Up to 5 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML20713
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.